ELIEM THERAPEUTICS INC (ELYM) Stock News
NASDAQ:ELYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD
ELYM Latest News, Press Relases and Analysis
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Name change to
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the...
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the second quarter o...
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024
Eliem Therapeutics just reported results for the second quarter of 2024.
Eliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...
Eliem Therapeutics Announces Additions to its Leadership Team
Eliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to...
Eliem Therapeutics Reports Second Quarter Financial Results
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024
Eliem Therapeutics just reported results for the first quarter of 2024.
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the fourth quarter o...
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will...
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus,...
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023
Eliem Therapeutics just reported results for the fourth quarter of 2023.
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...